Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mephenoxalone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.54 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.53 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.53 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | SYK | P43405 | 9/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mephenoxalone SCHEMBL4621926 | 0.99 | PKM (0.77) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL935967 | 0.99 | PKM (0.77) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL5392 | 0.99 | PKM (0.77) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL7117835 | 0.97 | PKM (0.75) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL22472152 | 0.97 | PKM (0.75) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL2175454 | 0.97 | PKM (0.75) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL7938104 | 0.97 | PKM (0.75) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL6098064 | 0.97 | PKM (0.75) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL1969509 | 0.97 | PKM (0.75) | PKMSYKADRA2CLMNAMAOA | |
| Mephenoxalone SCHEMBL6492968 | 0.96 | PKM (0.73) | PKMSYKADRA2CLMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025025434-A1 | EGFR/C-MET BISPECIFIC ANTIBODY AND USE THEREOF | 百泰生物药业有限公司 | 2025-02-06 | — | — | WO | disclosed |
| CN-116768813-B | Pleuromutilin derivatives, uses and pharmaceutical compositions thereof | 西华大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-116768813-A | Pleuromutilin derivatives, uses and pharmaceutical compositions thereof | 西华大学 | 2023-09-19 | — | — | CN | disclosed |
| EP-2451803-B1 | METHOD FOR PREPARING 5-CHLORO-N-({(5S)-2-OXO-3-[4-(5,6-DIHYDRO-4H-[1,2,4]TRIAZIN-1-YL)PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)THIOPHEN-2-CARBOXAMIDE DERIVATIVE AND INTERMEDIATE USED THEREIN | GREEN CROSS CORP (KR) | 2017-12-27 | — | — | EP | disclosed |
| US-8754210-B2 | Method for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl) derivative and intermediate used therein | GREEN CROSS CORPORATION (KR) | 2014-06-17 | — | — | US | disclosed |
| US-20120136149-A1 | METHOD FOR PREPARING 5-CHLORO-N-(METHYL)THIOPHEN-2-CARBOXAMIDE DERIVATIVE AND INTERMEDIATE USED THEREIN | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-05-31 | — | — | US | disclosed |
| EP-2451803-A2 | METHOD FOR PREPARING 5-CHLORO-N-({(5S)-2-OXO-3-[4-(5,6-DIHYDRO-4H-[1,2,4]TRIAZIN-1-YL)PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)THIOPHEN-2-CARBOXAMIDE DERIVATIVE AND INTERMEDIATE USED THEREIN | Green Cross Corporation (KR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005029-A2 | METHOD FOR PREPARING 5-CHLORO-N-({(5S)-2-OXO-3-[4-(5,6-DIHYDRO-4H-[1,2,4]TRIAZIN-1-YL)PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)THIOPHEN-2-CARBOXAMIDE DERIVATIVE AND INTERMEDIATE USED THEREIN | GREEN CROSS CORPORATION (KR) | 2011-01-13 | — | — | WO | disclosed |
| US-20040053270-A1 | RNA binding compounds and uses thereof | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-03-18 | — | — | US | disclosed |
| EP-1373562-A2 | METHOD FOR DETERMINING WHETHER A TEST COMPOUND BINDS TO A LARGE RNA TARGET | Vernalis (Cambridge) Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002014545-A2 | METHOD FOR DETERMINING WEATHER A TEST COMPOUND BINDS TO A LARGE RNA TARGET | RIBOTARGETS LIMITED (GB) | 2002-02-21 | — | — | WO | disclosed |
| EP-0681474-B1 | PHARMACEUTICAL COMPOSITION CONTAINING 5-MORPHOLINOMETHYL-3-(4-CHLOROBENZYLIDENEAMINE)-2-OXAZOLIDINONE AND ITS USE FOR THE TREATMENT OF CNS DISORDERS | INST FARMACEUTYCZNY (PL) | 1999-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136149-A1 | METHOD FOR PREPARING 5-CHLORO-N-(METHYL)THIOPHEN-2-CARBOXAMIDE DERIVATIVE AND INTERMEDIATE USED THEREIN | TFPI, F2, F9 | ADRA2C 3384/4885MAOA 786/4885SLC6A2 4790/4885 |
| US-20040053270-A1 | RNA binding compounds and uses thereof | FBL, EMG1, NSUN3 | ADRA2C 4631/4885MAOA 3380/4885SLC6A2 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.